Tissue equivalence correction for silicon microdosimetry detectors in boron neutron capture therapy

Bradley, Peter D.; Rosenfeld, Anatoly B.

doi:10.1118/1.598421

Cited by 39 publications

(18 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is a very primitive method and a more sophisticated method using a highly accurate monitoring system equipped with small-sized sensor that does not disturb the dose distribution in the radiation field should be developed. A semiconductor dosimeter is promising for this purpose 18 . The third problem is the difficulty in directly measuring the 20 , however, the sensitivity of this method is too low for practical use.…”

Section: Discussionmentioning

confidence: 99%

Boron neutron capture therapy (BNCT) for malignant melanoma with special reference to absorbed doses to the normal skin and tumor

Fukuda

Hoshino

Kobayashi

et al. 2003

Australas. Phys. Eng. Sci. Med.

View full text Add to dashboard Cite

Twenty-two patients with malignant melanoma were treated with boron neutron capture therapy (BNCT) using 10B-p-boronophenylalanine (BPA). The estimation of absorbed dose and optimization of treatment dose based on the pharmacokinetics of BPA in melanoma patients is described. The doses of gamma-rays were measured using small TLDs of Mg2SiO4 (Tb) and thermal neutron fluence was measured using gold foil and wire. The total absorbed dose to the tissue from BNCT was obtained by summing the primary and capture gamma-ray doses and the high LET radiation doses from 10B(n, alpha)7Li and 14N(n,p)14C reactions. The key point of the dose optimization is that the skin surrounding the tumour is always irradiated to 18 Gy-Eq, which is the maximum tolerable dose to the skin, regardless of the 10B-concentration in the tumor. The neutron fluence was optimized as follows. (1) The 10B concentration in the blood was measured 15-40 min after the start of neutron irradiation. (2) The 10B-concentration in the skin was estimated by multiplying the blood 10B value by a factor of 1.3. (3) The neutron fluence was calculated. Absorbed doses to the skin ranged from 15.7 to 37.1 Gy-Eq. Among the patients, 16 out of 22 patients exhibited tolerable skin damage. Although six patients showed skin damage that exceeded the tolerance level, three of them could be cured within a few months after BNCT and the remaining three developed severe skin damage requiring skin grafts. The absorbed doses to the tumor ranged from 15.7 to 68.5 Gy-Eq and the percentage of complete response was 73% (16/22). When BNCT is used in the treatment of malignant melanoma, based on the pharmacokinetics of BPA and radiobiological considerations, promising clinical results have been obtained, although many problems and issues remain to be solved.

show abstract

Section: Discussionmentioning

confidence: 99%

Boron neutron capture therapy (BNCT) for malignant melanoma with special reference to absorbed doses to the normal skin and tumor

Fukuda

Hoshino

Kobayashi

et al. 2003

Australas. Phys. Eng. Sci. Med.

View full text Add to dashboard Cite

show abstract

“…The reader should note we are attempting to make a direct comparison between the LET spectrum measured in a tissue equivalent gas, to that measured in silicon. Using a rationale similar to that reported for the case of BNCT [4], the mean chord length of the silicon volume was scaled to facilitate agreement in the lineal energy of the proton peak.…”

Section: Resultsmentioning

confidence: 99%

“…Silicon microdosimetry studies using SOI devices in radiation oncology have been reported previously [2]- [5]. In these studies, silicon microdosimeters were used to measure lineal energy spectra in such radiation oncology modalities as boron-neutron capture therapy (BNCT) [3], [4] and Proton therapy [2]. Recently the technique has been applied to measurements in fast neutron therapy (FNT).…”

mentioning

confidence: 99%

A computational technique for simulating ionization energy deposition by energetic ions in complex targets

Cornelius

Rosenfeld

Bradley

et al. 2000

IEEE Trans. Nucl. Sci.

View full text Add to dashboard Cite

show abstract

“…Bradley and co-authors addressed the issue of tissue equivalence of silicon based microdosimetric measurements in the special case of Boron Neutron Capture Therapy (BNCT) radiation fields [7]. The tissue equivalence of a first generation silicon microdosimeter, based on a parallelepiped (RPP) silicon detector, was investigated.…”

Section: Authorsmentioning

confidence: 99%

Tissue Equivalence Correction in Silicon Microdosimetry for Protons Characteristic of the LEO Space Environment

Guatelli

Reinhard

Mascialino

et al. 2008

IEEE Trans. Nucl. Sci.

Self Cite

View full text Add to dashboard Cite

Abstract-The tissue equivalence of solid state silicon detectors in proton radiation fields was determined to improve the radiation protection applications of silicon detectors in aviation and space missions. The study was performed by means of Geant4 simulations. Results are presented showing that a simple geometrical scaling factor (~0.56) of linear dimensions is adequate to convert experimentally obtained microdosimetric energy deposition spectra in silicon to equivalent microdosimetric energy deposition spectra in water.

show abstract

Tissue equivalence correction for silicon microdosimetry detectors in boron neutron capture therapy

Cited by 39 publications

References 16 publications

Boron neutron capture therapy (BNCT) for malignant melanoma with special reference to absorbed doses to the normal skin and tumor

Boron neutron capture therapy (BNCT) for malignant melanoma with special reference to absorbed doses to the normal skin and tumor

A computational technique for simulating ionization energy deposition by energetic ions in complex targets

Tissue Equivalence Correction in Silicon Microdosimetry for Protons Characteristic of the LEO Space Environment

Contact Info

Product

Resources

About